Jim Simons Akebia Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 3,952,727 shares of AKBA stock, worth $6.72 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

3,952,727

Previous 4,194,427 5.76%

Holding current value

$6.72 Million

Previous $15.3 Million 30.1%

% of portfolio

0.02%

Previous 0.02%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$2.7 - $4.01 $652,590 - $969,217	-241,700 Reduced 5.76%	3,952,727 $10.7 Million
Q2 2025 Aug 13, 2025	BUY	$1.55 - $3.97 $292,330 - $748,742	188,600 Added 4.71%	4,194,427 $15.3 Million
Q1 2025 May 14, 2025	BUY	$1.69 - $2.84 $308,087 - $517,732	182,300 Added 4.77%	4,005,827 $7.69 Million
Q4 2024 Feb 13, 2025	BUY	$1.26 - $2.13 $133,216 - $225,198	105,727 Added 2.84%	3,823,527 $7.11 Million
Q3 2024 Nov 13, 2024	SELL	$0.94 - $1.55 $185,180 - $305,350	-197,000 Reduced 5.03%	3,717,800 $4.91 Million

Q2 2024 Aug 09, 2024	BUY	$0.86 - $1.63 $225,922 - $428,201	262,700 Added 7.19%	3,914,800 $3.99 Million
Q1 2024 May 13, 2024	SELL	$1.27 - $2.24 $1.43 Million - $2.53 Million	-1,127,283 Reduced 23.59%	3,652,100 $6.68 Million
Q4 2023 Feb 13, 2024	BUY	$0.8 - $1.28 $1.3 Million - $2.08 Million	1,623,956 Added 51.47%	4,779,383 $5.93 Million
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.84 $152,511 - $322,552	-175,300 Reduced 5.26%	3,155,427 $3.6 Million
Q2 2023 Aug 11, 2023	BUY	$0.51 - $1.43 $506,035 - $1.42 Million	992,227 Added 42.43%	3,330,727 $3.05 Million
Q1 2023 May 12, 2023	SELL	$0.56 - $1.15 $306,727 - $629,886	-547,727 Reduced 18.98%	2,338,500 $1.31 Million
Q4 2022 Feb 13, 2023	SELL	$0.25 - $0.58 $32,550 - $75,516	-130,200 Reduced 4.32%	2,886,227 $1.67 Million
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $460,238 - $705,698	1,534,127 Added 103.5%	3,016,427 $954,000
Q2 2022 Aug 12, 2022	BUY	$0.32 - $0.67 $153,271 - $320,911	478,973 Added 47.74%	1,482,300 $523,000
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $273,816 - $1.11 Million	380,300 Added 61.04%	1,003,327 $720,000
Q4 2021 Feb 11, 2022	SELL	$2.26 - $3.34 $738,793 - $1.09 Million	-326,900 Reduced 34.41%	623,027 $1.41 Million
Q3 2021 Nov 12, 2021	SELL	$2.35 - $3.88 $2.06 Million - $3.41 Million	-877,803 Reduced 48.03%	949,927 $2.74 Million
Q2 2021 Aug 13, 2021	BUY	$2.83 - $4.2 $2.14 Million - $3.18 Million	757,149 Added 70.72%	1,827,730 $6.93 Million
Q1 2021 May 13, 2021	SELL	$2.92 - $5.06 $1.1 Million - $1.91 Million	-377,346 Reduced 26.06%	1,070,581 $3.62 Million
Q4 2020 Feb 10, 2021	BUY	$2.22 - $3.78 $3.06 Million - $5.21 Million	1,377,752 Added 1963.31%	1,447,927 $4.05 Million
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $13,178 - $72,123	-5,514 Reduced 7.29%	70,175 $176,000
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $504,845 - $1.03 Million	75,689 New	75,689 $1.03 Million
Q1 2020 May 14, 2020	SELL	$4.1 - $10.24 $567,960 - $1.42 Million	-138,527 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$3.16 - $6.73 $300,516 - $640,023	95,100 Added 218.99%	138,527 $875,000
Q3 2019 Nov 13, 2019	BUY	$3.55 - $5.4 $154,165 - $234,505	43,427 New	43,427 $170,000

Others Institutions Holding AKBA

# of Institutions

189

Shares Held

121M

Call Options Held

267K

Put Options Held

280K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $313M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account